CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,044 enrolled
Drug / intervention
Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)device
Likely dose
CRT-D device programming optimization during standard of care visits in first 12 months post-implantationAI-extracted
Key inclusion· 4
  • Implanted or upgraded with NG3 or NG4 CRT-D device connected with any manufacturer quadripolar LV lead per BSC labeling
  • Enrollment between 1 and 21 calendar days post-implantation
  • Age ≥18 years or legal age per country/national law
  • Willing and capable of complying with follow-up visits and procedures per protocol
Key exclusion· 6
  • Documented life expectancy <12 months
  • Currently on active heart transplant list or has LVAD or other mechanical circulatory support device
  • Pre-existing CRT device
  • Enrolled in concurrent clinical trial without prior written BSC approval

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03075215
NCT03075215N/ACompleted

Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry (SMART Registry)

Boston Scientific Corporation·observational·Posted Mar 9, 2017·Updated Oct 25, 2023

In Brief

An observational study evaluating Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) for Heart Failure. Completed, enrolled 2,044 participants across 139 sites in 15 countries.

Detailed Summary

To learn in a general Cardiac Resynchronization Therapy Defibrillators (CRT-D) population, which optimization techniques are used and how effective they are. It will compare 12-month response rates among different optimization methods and characterize which selected subject subgroups achieve better response than others. A subset of SMART Registry subjects will contribute to the NG4 Post Market Clinical Follow Up (PMCF) Cohort whose objective is collecting data on the NG4 CRT-D features and device usage in a real world setting and monitor long term safety associated with these devices to support CE Mark.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesAustralia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Netherlands, Portugal, Slovakia, Spain, Switzerland, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 9, 2017
Enrollment StartApr 14, 2017
Primary CompletionNov 15, 2021
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 9.3 years ago

Interventions

Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)device

The optimization during the standard of care visits in the first 12 months following implantation